JUPITER II is an international multi-centre double blind randomised clinical trial investigation
for the treatment of stenosis of coronary lesions with Janus Carbostent.
The results lend further support to the encouraging clinical data seen to date in lymphomas and warrant continued preclinical and clinical trial investigation
of darinaparsin in Hodgkin's and T Cell Lymphoma.
Although BOTOX(R) was first approved by the FDA in 1989, clinical trial investigations
began over 20 years ago.